STAT6 and Hepatic fibrosis: Oral administration of a bioactive chitooligosaccharide limits liver fibrosis in CCl4-exposed mice through mechanisms implicating the JAK1/STAT6 pathway in M2 macrophages/Kupffer cells (Liu et al., 2022).